Squamous Cell Anal Carcinoma: Current Therapeutic Approaches

Area of Science:

• Oncology
• Virology

Background:

• Anal squamous cell carcinoma (SCAC) is a rare but increasing malignancy.
• Human papillomavirus (HPV) is the primary cause of SCAC.
• Immunosuppression increases susceptibility to SCAC.

Purpose of the Study:

• To summarize the current understanding of SCAC epidemiology, diagnosis, and treatment.
• To highlight advancements in managing both localized and metastatic SCAC.
• To discuss emerging research in HPV-targeted therapies and immunotherapies.

Main Methods:

• Review of current literature on SCAC.
• Analysis of epidemiological trends and etiological drivers.
• Evaluation of standard and novel treatment modalities.

Main Results:

• Concurrent chemoradiotherapy is standard for localized SCAC, yielding high survival rates.
• Systemic therapy, including platinum-based chemotherapy and immunotherapy combinations, is used for metastatic SCAC.
• HPV vaccination and treatment of high-grade squamous intraepithelial lesions (HSIL) reduce cancer risk.

Conclusions:

• SCAC management requires a multi-faceted approach, from prevention to advanced disease treatment.
• Ongoing research in immunotherapy and HPV-targeting strategies shows promise for improving patient outcomes.
• Early intervention and risk factor management are crucial for controlling SCAC incidence and progression.